Information:
Fel:
ID
37225
Beskrivning
SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02500914
Länk
https://clinicaltrials.gov/show/NCT02500914
Nyckelord
Versioner (1)
- 2019-07-08 2019-07-08 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
8 juli 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Small Cell Lung Cancer NCT02500914
Eligibility Small Cell Lung Cancer NCT02500914
- StudyEvent: Eligibility
Similar models
Eligibility Small Cell Lung Cancer NCT02500914
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Small cell carcinoma of lung | Small cell lung cancer limited stage | Small cell lung cancer extensive stage | Large cell neuroendocrine carcinoma of lung Relapse | Large cell neuroendocrine carcinoma of lung Unresponsive to Treatment
Item
histologically or cytologically confirmed sclc (either limited or extensive disease) or lcnec, that has relapsed from the most current treatment or was refractory to treatment
boolean
C0149925 (UMLS CUI [1])
C0278725 (UMLS CUI [2])
C0278726 (UMLS CUI [3])
C1334363 (UMLS CUI [4,1])
C0277556 (UMLS CUI [4,2])
C1334363 (UMLS CUI [5,1])
C0205269 (UMLS CUI [5,2])
C0278725 (UMLS CUI [2])
C0278726 (UMLS CUI [3])
C1334363 (UMLS CUI [4,1])
C0277556 (UMLS CUI [4,2])
C1334363 (UMLS CUI [5,1])
C0205269 (UMLS CUI [5,2])
Progressive Disease | Chemotherapy Regimen Quantity
Item
evidence of progressive disease during or following no more than 2 prior chemotherapy regimens
boolean
C1335499 (UMLS CUI [1])
C0392920 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0392920 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
Measurable Disease
Item
measurable disease as defined by recist
boolean
C1513041 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Hematologic function | Organ function | Laboratory Results
Item
adequate hematological and organ function as confirmed by laboratory values
boolean
C0221130 (UMLS CUI [1])
C0678852 (UMLS CUI [2])
C1254595 (UMLS CUI [3])
C0678852 (UMLS CUI [2])
C1254595 (UMLS CUI [3])
Antineoplastic Agents | Investigational New Drugs | SC002
Item
treatment with anticancer/investigational drugs, therapy ≤ 4 weeks prior to first dose of sc-002
boolean
C0003392 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0967624 (UMLS CUI [3])
C0013230 (UMLS CUI [2])
C0967624 (UMLS CUI [3])
CNS metastases
Item
active central nervous system metastases
boolean
C0686377 (UMLS CUI [1])
Heart Disease Uncontrolled
Item
uncontrolled cardiac disease
boolean
C0018799 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,2])
Hepatitis B Serology positive | Hepatitis C Serology positive | HIV Seropositivity
Item
positive serology for hepatitis b or hepatitis c or known hiv infection
boolean
C0019163 (UMLS CUI [1,1])
C0242089 (UMLS CUI [1,2])
C0019196 (UMLS CUI [2,1])
C0242089 (UMLS CUI [2,2])
C0019699 (UMLS CUI [3])
C0242089 (UMLS CUI [1,2])
C0019196 (UMLS CUI [2,1])
C0242089 (UMLS CUI [2,2])
C0019699 (UMLS CUI [3])
Condition Study Subject Participation Status At risk | Condition Interferes with Interpretation Research results
Item
presence of any condition that may increase the risks associated with study participation and interfere with the interpretation of study results
boolean
C0348080 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1444641 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0459471 (UMLS CUI [2,3])
C0683954 (UMLS CUI [2,4])
C2348568 (UMLS CUI [1,2])
C1444641 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0459471 (UMLS CUI [2,3])
C0683954 (UMLS CUI [2,4])